Home  
  Our Team  
  Patient Info  
  Services  
   
  Pay My Bill  
  Contact Us  

News for Healthier Living

Teclistamab Extends Survival, Deepens Remissions in Relapsed Multiple Myeloma in Landmark International Trial

NEJM/ASCO 2026: A global phase 3 trial found the bispecific immunotherapy teclistamab significantly improved survival and remission in relapsed multiple myeloma, with nearly 70% of patients progression-free at 18 months, outperforming standard therapies.

May 29, 2026


June 3 2026

June 2 2026

June 1 2026

May 31 2026

May 30 2026

May 29 2026

May 28 2026

May 27 2026

May 26 2026

May 25 2026

May 22 2026

May 21 2026